Spots Global Cancer Trial Database for Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Official Title: A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma
Study ID: NCT03778073
Study Description
Brief Summary: Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
Detailed Description: This study will evaluate the safety profile, pharmacokinetics, and efficacy of single-agent cosibelimab as well as the combination of Cosibelimab + Ublituximab + Bendamustin.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States
TG Therapeutics Investigational Trial Site, Tucson, Arizona, United States
TG Therapeutics Investigational Trial Site, Fayetteville, Arkansas, United States
TG Therapeutics Investigational Trial Site, Peoria, Illinois, United States
TG Therapeutics Investigational Trial Site, Fort Wayne, Indiana, United States
TG Therapeutics Investigational Trial Site, Fairway, Kansas, United States
TG Therapeutics Investigational Trial Site, Louisville, Kentucky, United States
TG Therapeutics Investigational Trial Site, Charlotte, North Carolina, United States
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
